In Silico Investigations of the Anti-Catabolic Effects of Pamidronate and Denosumab on Multiple Myeloma-Induced Bone Disease
Figure 4
The calibration and validation of the pharmacokinetic models of pamidronate and denosumab.
(a) The calibration of the pharmacokinetic model of denosumab. (b) The validation of the pharmacokinetic model of denosumab. (c) The calibration of the pharmacokinetic model of pamidronate. (d) The validation of the pharmacokinetic model of pamidronate.